NOVEL RADIOLABELED PEPTIDES FOR NON-INVASIVE BREAST CANCER IMAGING

用于非侵入性乳腺癌成像的新型放射性标记肽

• 批准号: 8359764
• 负责人: Yubin Miao
• 金额: $ 10.74万
• 依托单位: NEW MEXICO STATE UNIVERSITY LAS CRUCES
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8359764
• 关键词: Biomedical Research; Breast Cancer Cell; Cancer Etiology; Cessation of life; Deoxyglucose; Detection; Diagnostic; Early Diagnosis; Funding; Gonadotropin Hormone Releasing Hormone; Gonadotropin-Releasing Hormone Receptor; Grant; Image; Metastatic/Recurrent; Molecular Target; National Center for Research Resources; New Mexico; Patients; Peptides; Positron-Emission Tomography; Principal Investigator; Radiolabeled; Research; Research Design; Research Infrastructure; Resources; Second Primary Cancers; Sensitivity and Specificity; Series; Source; Specimen; Therapeutic Agents; United States National Institutes of Health; Woman; Xenograft procedure; cancer diagnosis; cancer imaging; cost; design; imaging probe; improved; insight; malignant breast neoplasm; novel; radiotracer

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in women. Unfortunately, no curative treatment exists for metastatic breast cancer. Early diagnosis of breast cancer provides the patients the best opportunities for cures or prolonged survival. Current [18F]FDG (2-[18F]fluoro-2-deoxy-D-glucose) PET (positron emission tomography) imaging has limited use by relatively low sensitivity and specificity. Novel and more effective imaging probes are urgently needed to improve the detection accuracy of primary, metastatic and recurrent breast cancers. Our strategy to improve the detection accuracy for breast cancer focuses on developing novel radiolabeled gonadotropin-releasing hormone (GnRH) peptides to target the GnRH receptors. GnRH receptor is a distinct molecular target in this project for developing more effective breast cancer-specific imaging probes due to its over-expression on human breast cancer cells and specimens. We will synthesize and evaluate a series of novel radiolabeled GnRH peptides in human breast cancer cells and xenografts in this project. Our central hypothesis and research design are strongly supported by our positive preliminary results. Positive results from this project will firstly demonstrate the feasibility of using the radiolabeled GnRH peptides for breast cancer imaging and provide new insight into the design of novel and more effective diagnostic and therapeutic agents for breast cancer.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 子项目的主要研究者可能是由其他来源提供的， 包括其他NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 乳腺癌是最常见的癌症，也是妇女癌症死亡的第二大原因。不幸的是，对于转移性乳腺癌不存在治愈性治疗。乳腺癌的早期诊断为患者提供了治愈或延长生存期的最佳机会。目前的[18 F]FDG（2-[18 F]氟-2-脱氧-D-葡萄糖）PET（正电子发射断层扫描）成像由于相对较低的灵敏度和特异性而限制了其使用。迫切需要新的和更有效的成像探针来提高原发性、转移性和复发性乳腺癌的检测准确性。 我们的策略，以提高乳腺癌的检测准确性，重点是开发新的放射性标记的促性腺激素释放激素（GnRH）肽靶向GnRH受体。由于GnRH受体在人乳腺癌细胞和标本中的过表达，因此GnRH受体是本项目开发更有效的乳腺癌特异性成像探针的独特分子靶标。本研究拟合成一系列新型的放射性标记GnRH肽，并在人乳腺癌细胞和异种移植瘤中进行评价。我们的中心假设和研究设计得到了我们积极的初步结果的有力支持。该项目的阳性结果将首次证明放射性标记的GnRH肽用于乳腺癌成像的可行性，并为设计新型和更有效的乳腺癌诊断和治疗药物提供新的见解。